Anxiety and Depression Treatment Market Research Report: By Product Type (Drugs, Devices), Disorder Type (Major Depressive Disorder, OCD, Phobia, PTSD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channels, Direct Channels) - Global Industry Analysis and Demand Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Product Type

1.5.2 Drugs Market Segmentation by Disorder Type

1.5.3 Drugs Market Segmentation by Distribution Channel

1.5.4 Market Segmentation by Region

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Region

2.2.2 Breakdown of Primary Research, by Industry Participant

2.2.3 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

5.1 Prevalence of Mental Disorders

Chapter 6. Definition of Market Segments

6.1 By Product Type

6.1.1 Drugs

6.1.1.1 Antidepressants

6.1.1.1.1 SSRIs

6.1.1.1.2 SNRIs

6.1.1.1.3 TCAs

6.1.1.1.4 MAOIs

6.1.1.1.5 Others

6.1.1.2 Anticonvulsants

6.1.1.3 Atypical antipsychotics

6.1.1.4 Benzodiazepines

6.1.1.5 Beta-blockers

6.1.2 Devices

6.2 By Disorder Type

6.2.1 Major Depressive Disorder

6.2.2 OCD

6.2.3 Phobia

6.2.4 PTSD

6.2.5 Others

6.3 By Distribution Channel

6.3.1 Hospital Pharmacies

6.3.2 Retail Pharmacies

6.3.3 Online Channels

6.3.4 Direct Channels

Chapter 7. Industry Outlook

7.1 Market Dynamics

7.1.1 Trends

7.1.1.1 Increasing number of mergers and acquisitions

7.1.2 Drivers

7.1.2.1 Increasing aging population

7.1.2.2 Growing awareness about mental diseases and their treatment

7.1.2.3 Rising number of product approvals

7.1.2.4 Impact analysis of drivers on market forecast

7.1.3 Restraints

7.1.3.1 Side effects associated with usage of drugs and devices

7.1.3.2 Availability of complementary and alternative medicines

7.1.3.3 Impact analysis of restraints on market forecast

7.1.4 Opportunities

7.1.4.1 Emerging economies are key opportunity areas for market players

7.2 Impact of COVID-19

7.3 Porter’s Five Forces Analysis

7.3.1 Bargaining Power of Buyers

7.3.2 Bargaining Power of Suppliers

7.3.3 Intensity of Rivalry

7.3.4 Threat of New Entrants

7.3.5 Threat of Substitutes

Chapter 8. Global Market Size and Forecast

8.1 Overview

8.2 Market Revenue, by Product Type (2025–2030)

8.2.1 Drugs Market Revenue, by Type (2025–2030)

8.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

8.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

8.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

8.3 Market Revenue, by Region (2025–2030)

Chapter 9. North America Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Product Type (2025–2030)

9.2.1 Drugs Market Revenue, by Type (2025–2030)

9.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

9.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

9.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

9.3 Market Revenue, by Country (2025–2030)

Chapter 10. Europe Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Product Type (2025–2030)

10.2.1 Drugs Market Revenue, by Type (2025–2030)

10.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

10.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

10.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

10.3 Market Revenue, by Country (2025–2030)

Chapter 11. APAC Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Product Type (2025–2030)

11.2.1 Drugs Market Revenue, by Type (2025–2030)

11.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

11.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

11.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

11.3 Market Revenue, by Country (2025–2030)

Chapter 12. LATAM Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Product Type (2025–2030)

12.2.1 Drugs Market Revenue, by Type (2025–2030)

12.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

12.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

12.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

12.3 Market Revenue, by Country (2025–2030)

Chapter 13. MEA Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Product Type (2025–2030)

13.2.1 Drugs Market Revenue, by Type (2025–2030)

13.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

13.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

13.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

13.3 Market Revenue, by Country (2025–2030)

Chapter 14. U.S. Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Product Type (2025–2030)

14.2.1 Drugs Market Revenue, by Type (2025–2030)

14.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

14.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

14.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 15. Canada Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Product Type (2025–2030)

15.2.1 Drugs Market Revenue, by Type (2025–2030)

15.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

15.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

15.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 16. Germany Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Product Type (2025–2030)

16.2.1 Drugs Market Revenue, by Type (2025–2030)

16.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

16.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

16.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 17. France Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Product Type (2025–2030)

17.2.1 Drugs Market Revenue, by Type (2025–2030)

17.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

17.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

17.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 18. U.K. Market Size and Forecast

18.1 Overview

18.2 Market Revenue, by Product Type (2025–2030)

18.2.1 Drugs Market Revenue, by Type (2025–2030)

18.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

18.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

18.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 19. Italy Market Size and Forecast

19.1 Overview

19.2 Market Revenue, by Product Type (2025–2030)

19.2.1 Drugs Market Revenue, by Type (2025–2030)

19.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

19.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

19.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 20. Spain Market Size and Forecast

20.1 Overview

20.2 Market Revenue, by Product Type (2025–2030)

20.2.1 Drugs Market Revenue, by Type (2025–2030)

20.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

20.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

20.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 21. China Market Size and Forecast

21.1 Overview

21.2 Market Revenue, by Product Type (2025–2030)

21.2.1 Drugs Market Revenue, by Type (2025–2030)

21.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

21.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

21.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 22. Japan Market Size and Forecast

22.1 Overview

22.2 Market Revenue, by Product Type (2025–2030)

22.2.1 Drugs Market Revenue, by Type (2025–2030)

22.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

22.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

22.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 23. India Market Size and Forecast

23.1 Overview

23.2 Market Revenue, by Product Type (2025–2030)

23.2.1 Drugs Market Revenue, by Type (2025–2030)

23.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

23.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

23.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 24. Australia Market Size and Forecast

24.1 Overview

24.2 Market Revenue, by Product Type (2025–2030)

24.2.1 Drugs Market Revenue, by Type (2025–2030)

24.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

24.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

24.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 25. South Korea Market Size and Forecast

25.1 Overview

25.2 Market Revenue, by Product Type (2025–2030)

25.2.1 Drugs Market Revenue, by Type (2025–2030)

25.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

25.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

25.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 26. Brazil Market Size and Forecast

26.1 Overview

26.2 Market Revenue, by Product Type (2025–2030)

26.2.1 Drugs Market Revenue, by Type (2025–2030)

26.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

26.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

26.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 27. Mexico Market Size and Forecast

27.1 Overview

27.2 Market Revenue, by Product Type (2025–2030)

27.2.1 Drugs Market Revenue, by Type (2025–2030)

27.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

27.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

27.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 28. Saudi Arabia Market Size and Forecast

28.1 Overview

28.2 Market Revenue, by Product Type (2025–2030)

28.2.1 Drugs Market Revenue, by Type (2025–2030)

28.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

28.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

28.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 29. South Africa Market Size and Forecast

29.1 Overview

29.2 Market Revenue, by Product Type (2025–2030)

29.2.1 Drugs Market Revenue, by Type (2025–2030)

29.2.1.1 Antidepressants drugs market revenue, by type (2025–2030)

29.2.2 Drugs Market Revenue, by Disorder Type (2025–2030)

29.2.3 Drugs Market Revenue, by Distribution Channel (2025–2030)

Chapter 30. Competitive Landscape

30.1 List of Market Players and Their Offerings

30.2 Product Benchmarking

30.3 Recent Strategic Developments of Key Players

30.3.1 Product Launches and Approvals

30.3.2 Mergers and Acquisitions

30.3.3 Others

Chapter 31. Company Profiles

31.1 Novartis AG

31.1.1 Business Overview

31.1.2 Product and Service Offerings

31.1.3 Key Financial Summary

31.2 Pfizer Inc.

31.2.1 Business Overview

31.2.2 Product and Service Offerings

31.2.3 Key Financial Summary

31.3 Bristol-Myers Squibb Company

31.3.1 Business Overview

31.3.2 Product and Service Offerings

31.3.3 Key Financial Summary

31.4 Johnson & Johnson

31.4.1 Business Overview

31.4.2 Product and Service Offerings

31.4.3 Key Financial Summary

31.5 Merck & Co. Inc.

31.5.1 Business Overview

31.5.2 Product and Service Offerings

31.5.3 Key Financial Summary

31.6 AbbVie Inc.

31.6.1 Business Overview

31.6.2 Product and Service Offerings

31.6.3 Key Financial Summary

31.7 Eli Lilly and Company

31.7.1 Business Overview

31.7.2 Product and Service Offerings

31.7.3 Key Financial Summary

31.8 GlaxoSmithKline plc

31.8.1 Business Overview

31.8.2 Product and Service Offerings

31.8.3 Key Financial Summary

31.9 Sanofi

31.9.1 Business Overview

31.9.2 Product and Service Offerings

31.9.3 Key Financial Summary

31.10 H. Lundbeck A/S

31.10.1 Business Overview

31.10.2 Product and Service Offerings

31.10.2.1 Marketed products

31.10.2.2 Pipeline products

31.10.3 Key Financial Summary

31.11 Mylan N.V.

31.11.1 Business Overview

31.11.2 Product and Service Offerings

31.11.3 Key Financial Summary

31.12 Cipla Ltd.

31.12.1 Business Overview

31.12.2 Product and Service Offerings

31.12.3 Key Financial Summary

31.13 Glenmark Life Sciences Limited

31.13.1 Business Overview

31.13.2 Product and Service Offerings

31.13.3 Key Financial Summary

31.14 Lupin Limited

31.14.1 Business Overview

31.14.2 Product and Service Offerings

31.14.3 Key Financial Summary

31.15 Amneal Pharmaceuticals Inc.

31.15.1 Business Overview

31.15.2 Product and Service Offerings

31.15.3 Key Financial Summary

31.16 AstraZeneca plc

31.16.1 Business Overview

31.16.2 Product and Service Offerings

31.16.2.1 Marketed products

31.16.2.2 Pipeline products

31.16.3 Key Financial Summary

31.17 Sun Pharmaceutical Industries Ltd.

31.17.1 Business Overview

31.17.2 Product and Service Offerings

31.17.3 Key Financial Summary

31.18 Intas Pharmaceuticals Ltd.

31.18.1 Business Overview

31.18.2 Product and Service Offerings

31.18.3 Key Financial Summary

31.19 Sumitomo Dainippon Pharma Co. Ltd.

31.19.1 Business Overview

31.19.2 Product and Service Offerings

31.19.3 Key Financial Summary

Chapter 32. Appendix

32.1 Abbreviations

32.2 Sources and References

32.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 5 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 6 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 7 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 8 GLOBAL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 9 GLOBAL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 10 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 11 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 12 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 13 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 14 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY REGION, $M (2019–2024)

TABLE 15 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY REGION, $M (2021–2030)

TABLE 16 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 17 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 18 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 19 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 20 NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 21 NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 22 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 23 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 24 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 25 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 26 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 27 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 28 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 29 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 30 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 31 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 32 EUROPE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 33 EUROPE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 34 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 35 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 36 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 37 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 38 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 39 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 40 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 41 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 42 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 43 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 44 APAC ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 45 APAC ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 46 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 47 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 48 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 49 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 50 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 51 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 52 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 53 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 54 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 55 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 56 LATAM ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 57 LATAM ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 58 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 59 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 60 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 61 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 62 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 63 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 64 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 65 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 66 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 67 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 68 MEA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 69 MEA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 70 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 71 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 72 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 73 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 74 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 75 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 76 U.S. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 77 U.S. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 78 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 79 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 80 U.S. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 81 U.S. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 82 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 83 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 84 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 85 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 86 CANADA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 87 CANADA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 88 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 89 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 90 CANADA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 91 CANADA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 92 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 93 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 94 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 95 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 96 GERMANY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 97 GERMANY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 98 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 99 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 100 GERMANY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 101 GERMANY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 102 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 103 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 104 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 105 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 106 FRANCE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 107 FRANCE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 108 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 109 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 110 FRANCE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 111 FRANCE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 112 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 113 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 114 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 115 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 116 U.K. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 117 U.K. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 118 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 119 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 120 U.K. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 121 U.K. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 122 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 123 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 124 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 125 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 126 ITALY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 127 ITALY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 128 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 129 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 130 ITALY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 131 ITALY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 132 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 133 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 134 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 135 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 136 SPAIN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 137 SPAIN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 138 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 139 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 140 SPAIN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 141 SPAIN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 142 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 143 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 144 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 145 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 146 CHINA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 147 CHINA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 148 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 149 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 150 CHINA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 151 CHINA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 152 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 153 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 154 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 155 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 156 JAPAN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 157 JAPAN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 158 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 159 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 160 JAPAN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 161 JAPAN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 162 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 163 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 164 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 165 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 166 INDIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 167 INDIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 168 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 169 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 170 INDIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 171 INDIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 172 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 173 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 174 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 175 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 176 AUSTRALIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 177 AUSTRALIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 178 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 179 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 180 AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 181 AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 182 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 183 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 184 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 185 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 186 SOUTH KOREA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 187 SOUTH KOREA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 188 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 189 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 190 SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 191 SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 192 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 193 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 194 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 195 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 196 BRAZIL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 197 BRAZIL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 198 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 199 RAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 200 BRAZIL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 201 BRAZIL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 202 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 203 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 204 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 205 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 206 MEXICO ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 207 MEXICO ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 208 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 209 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 210 MEXICO ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 211 MEXICO ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 212 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 213 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 214 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 215 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 216 SAUDI ARABIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 217 SAUDI ARABIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 218 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 219 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 220 SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 221 SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 222 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 223 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 224 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 225 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 226 SOUTH AFRICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2019–2024)

TABLE 227 SOUTH AFRICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2021–2030)

TABLE 228 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 229 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 230 SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 231 SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 232 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2019–2024)

TABLE 233 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2021–2030)

TABLE 234 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 235 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2021–2030)

TABLE 236 LIST OF MARKET PLAYERS AND THEIR OFFERINGS

TABLE 237 PRODUCT BENCHMARKING

TABLE 238 NOVARTIS AG – AT A GLANCE

TABLE 239 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 240 PFIZER INC. – AT A GLANCE

TABLE 241 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 242 BRISTOL-MYERS SQUIBB COMPANY – AT A GLANCE

TABLE 243 BRISTOL-MYERS SQUIBB COMPANY – KEY FINANCIAL SUMMARY

TABLE 244 JOHNSON & JOHNSON – AT A GLANCE

TABLE 245 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY

TABLE 246 MERCK & CO. INC. – AT A GLANCE

TABLE 247 MERCK & CO. INC. – KEY FINANCIAL SUMMARY

TABLE 248 ABBVIE INC. – AT A GLANCE

TABLE 249 ABBVIE INC. – KEY FINANCIAL SUMMARY

TABLE 250 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 251 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 252 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 253 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 254 SANOFI – AT A GLANCE

TABLE 255 SANOFI – KEY FINANCIAL SUMMARY

TABLE 256 H. LUNDBECK A/S – AT A GLANCE

TABLE 257 MARKETED PRODUCTS

TABLE 258 PIPELINE PRODUCTS

TABLE 259 H. LUNDBECK A/S– KEY FINANCIAL SUMMARY

TABLE 260 MYLAN N.V. – AT A GLANCE

TABLE 261 MYLAN N.V. – KEY FINANCIAL SUMMARY

TABLE 262 CIPLA LTD. – AT A GLANCE

TABLE 263 CIPLA LTD. – KEY FINANCIAL SUMMARY

TABLE 264 GLENMARK LIFE SCIENCES LIMITED – AT A GLANCE

TABLE 265 GLENMARK LIFE SCIENCES LIMITED – KEY FINANCIAL SUMMARY

TABLE 266 LUPIN LIMITED – AT A GLANCE

TABLE 267 LUPIN LIMITED – KEY FINANCIAL SUMMARY

TABLE 268 AMNEAL PHARMACEUTICALS INC. – AT A GLANCE

TABLE 269 AMNEAL PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY

TABLE 270 ASTRAZENECA PLC – AT A GLANCE

TABLE 271 ASTRAZENECA PLC – KEY FINANCIAL SUMMARY

TABLE 272 SUN PHARMACEUTICAL INDUSTRIES LTD. – AT A GLANCE

TABLE 273 SUN PHARMACEUTICAL INDUSTRIES LTD. – KEY FINANCIAL SUMMARY

TABLE 274 INTAS PHARMACEUTICALS LTD. – AT A GLANCE

TABLE 275 INTAS PHARMACEUTICALS LTD. – KEY FINANCIAL SUMMARY

TABLE 276 SUMITOMO DAINIPPON PHARMA CO. LTD. – AT A GLANCE

TABLE 277 SUMITOMO DAINIPPON PHARMA CO. LTD. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 8 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET SUMMARY

FIG 9 VOICE OF INDUSTRY EXPERTS/KOLS

FIG 10 AVERAGE PREVALENCE OF MENTAL HEALTH DISORDERS FOR 2017 (IN MILLIONS)

FIG 11 PREVALENCE OF DEPRESSION IN MAJOR COUNTRIES (2000–2017)

FIG 12 PREVALENCE OF ANXIETY DISORDERS IN MAJOR COUNTRIES (2000–2017)

FIG 13 BARGAINING POWER OF BUYERS

FIG 14 BARGAINING POWER OF SUPPLIERS

FIG 15 INTENSITY OF RIVALRY

FIG 16 THREAT OF NEW ENTRANTS

FIG 17 THREAT OF SUBSTITUTES

FIG 18 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 19 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 20 GLOBAL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 21 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 22 GLOBAL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 23 GLOBAL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY REGION, $M (2025–2030)

FIG 24 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 25 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 26 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 27 NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 28 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 29 NORTH AMERICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 30 NORTH AMERICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 31 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 32 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 33 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 34 EUROPE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 35 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 36 EUROPE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 37 EUROPE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 38 APAC ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 39 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 40 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 41 APAC ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 42 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 43 APAC ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 44 APAC ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 45 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 46 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 47 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 48 LATAM ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 49 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 50 LATAM ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 51 LATAM ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 52 MEA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 53 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 54 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 55 MEA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 56 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 57 MEA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 58 MEA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 59 U.S. ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 60 U.S. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 61 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 62 U.S. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 63 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 64 U.S. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 65 CANADA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 66 CANADA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 67 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 68 CANADA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 69 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 70 CANADA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 71 GERMANY ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 72 GERMANY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 73 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 74 GERMANY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 75 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 76 GERMANY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 77 FRANCE ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 78 FRANCE ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 79 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 80 FRANCE ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 81 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 82 FRANCE ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 83 U.K. ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 84 U.K. ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 85 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 86 U.K. ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 87 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 88 U.K. ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 89 ITALY ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 90 ITALY ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 91 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 92 ITALY ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 93 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 94 ITALY ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 95 SPAIN ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 96 SPAIN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 97 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 98 SPAIN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 99 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 100 SPAIN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 101 CHINA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 102 CHINA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 103 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 104 CHINA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 105 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 106 CHINA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 107 JAPAN ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 108 JAPAN ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 109 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 110 JAPAN ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 111 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 112 JAPAN ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 113 INDIA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 114 INDIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 115 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 116 INDIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 117 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 118 INDIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 119 AUSTRALIA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 120 AUSTRALIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 121 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 122 AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 123 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 124 AUSTRALIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 125 SOUTH KOREA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 126 SOUTH KOREA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 127 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 128 SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 129 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 130 SOUTH KOREA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 131 BRAZIL ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 132 BRAZIL ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 133 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 134 BRAZIL ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 135 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 136 BRAZIL ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 137 MEXICO ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 138 MEXICO ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 139 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 140 MEXICO ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 141 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 142 MEXICO ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 143 SAUDI ARABIA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 144 SAUDI ARABIA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 145 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 146 SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 147 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 148 SAUDI ARABIA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 149 SOUTH AFRICA ANXIETY AND DEPRESSION TREATMENT MARKET SNAPSHOT

FIG 150 SOUTH AFRICA ANXIETY AND DEPRESSION TREATMENT MARKET REVENUE, BY PRODUCT TYPE, $M (2025–2030)

FIG 151 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 152 SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 153 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISORDER TYPE, $M (2025–2030)

FIG 154 SOUTH AFRICA ANXIETY AND DEPRESSION DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 155 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 156 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 157 BRISTOL-MYERS SQUIBB COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 158 JOHNSON & JOHNSON – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 159 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 160 ABBVIE INC. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2023)

FIG 161 ELI LILLY AND COMPANY – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)

FIG 162 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 163 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 164 H. LUNDBECK A/S. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 165 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)

FIG 166 CIPLA LTD. – REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2023)

FIG 167 GLENMARK LIFE SCIENCES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 168 LUPIN LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 169 AMNEAL PHARMACEUTICALS INC. – REVENUE SPLIT BY SEGMENT (2023)

FIG 170 ASTRAZENECA PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 171 SUN PHARMACEUTICAL INDUSTRIES LTD. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 172 INTAS PHARMACEUTICALS LTD. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 173 SUMITOMO DAINIPPON PHARMA CO. LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)